Rapid Drug Susceptibility Testing with a Molecular Beacon Assay Is Associated with Earlier Diagnosis and Treatment of Multidrug-Resistant Tuberculosis in California-Reference-Cited by-同舟云学术

Rapid Drug Susceptibility Testing with a Molecular Beacon Assay Is Associated with Earlier Diagnosis and Treatment of Multidrug-Resistant Tuberculosis in California

Published:2010-10 Issue:10 Volume:48 Page:3779-3781
ISSN:0095-1137
Container-title:Journal of Clinical Microbiology
language:en
Short-container-title:J Clin Microbiol

Author:

Banerjee Ritu¹,Allen Jennifer²,Lin S.-Y. Grace³,Westenhouse Janice²,Desmond Ed³,Schecter Gisela F.²,Scott Cheryl²,Raftery Ann⁴,Mase Sundari⁵,Watt James P.²,Flood Jennifer²

Affiliation:

1. Division of Pediatric Infectious Diseases, Mayo Clinic, Rochester, Minnesota

2. Tuberculosis Control Branch, Division of Communicable Disease, Center for Infectious Disease, California Department of Public Health, Richmond, California

3. Microbial Diseases Laboratory, Division of Communicable Disease, Center for Infectious Disease, California Department of Public Health, Richmond, California

4. Francis J. Curry National Tuberculosis Center, San Francisco, California

5. Division of Tuberculosis Elimination, Centers for Disease Control and Prevention, Atlanta, Georgia

Abstract

ABSTRACT To assess the clinical impact of a molecular beacon (MB) assay that detects multidrug-resistant tuberculosis (MDR TB), we retrospectively reviewed records of 127 MDR TB patients with and without MB testing between 2004 and 2007. Use of the MB assay reduced the time to detection and treatment of MDR TB.

Publisher

American Society for Microbiology

Subject

Microbiology (medical)

Link

https://journals.asm.org/doi/pdf/10.1128/JCM.01236-10

Reference10 articles.

1. Centers for Disease Control and Prevention. 2006. Emergence of Mycobacterium tuberculosis with extensive resistance to second-line drugs—worldwide, 2000-2004. MMWR Morb. Mortal. Wkly. Rep. 55 : 301-305.

2. Report of expert consultations on rapid molecular testing to detect drug-resistant tuberculosis in the United States 2009

3. Evaluation of a line probe assay kit for characterization of rpoB mutations in rifampin-resistant Mycobacterium tuberculosis isolates from New York City

4. Greenaway, C., D. Menzies, A. Fanning, R. Grewal, L. Yuan, J. M. Fitzgerald, and the Canadian Collaborative Group in Nosocomial Transmission of Tuberculosis. 2002. Delay in diagnosis among hospitalized patients with active tuberculosis—predictors and outcomes. Am. J. Respir. Crit. Care 165 : 927-933.

5. Rapid Detection of Isoniazid and Rifampin Resistance Mutations in Mycobacterium tuberculosis Complex from Cultures or Smear-Positive Sputa by Use of Molecular Beacons

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Evaluation of the Impact of a Sequencing Assay for Detection of Drug Resistance on the Clinical Management of Tuberculosis;Clinical Infectious Diseases;2018-11-01

2. The California Multidrug-Resistant Tuberculosis Consult Service: a partnership of state and local programs;Public Health Action;2018-03-21

3. Time to treatment for rifampicin-resistant tuberculosis: systematic review and meta-analysis;The International Journal of Tuberculosis and Lung Disease;2017-11-01

4. Multi-Fluorescence Real-Time PCR Assay for Detection of RIF and INH Resistance of M. tuberculosis;Frontiers in Microbiology;2016-04-29

5. Clinical Impact on Tuberculosis Treatment Outcomes of Discordance Between Molecular and Growth-Based Assays for Rifampin Resistance, California 2003–2013;Open Forum Infectious Diseases;2016